Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-Arterial CBL0137 for Advanced Extremity Melanoma or Sarcoma
NCT03727789Phase 1Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cbl0137 in melanoma and sarcoma, sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoint: Dose-limiting toxicities up to 24 months. Started Jul 2019; status: terminated.
02
Drugs
cbl0137
03
Conditions
melanomasarcoma
Beyond the preview
Go deeper on NCT03727789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03727789.